Citigroup
ALXN

Citigroup’s Alexion Pharmaceuticals ALXN Stock Holding History

Citigroup’s Portfolio ALXN Stock Details ALXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-44,000
Closed -$8.08M – 6556
2021
Q2 		$8.08M Hold
44,000
– – ﹤0.01% 1562
2021
Q1 		$6.73M Sell
44,000
-185,700
-81% -$28.7M ﹤0.01% 1610
2020
Q4 		$35.9M Buy
229,700
+13,500
+6% +$1.73M 0.02% 710
2020
Q3 		$24.7M Sell
216,200
-71,800
-25% -$7.75M 0.02% 795
2020
Q2 		$32.3M Sell
288,000
-31,100
-10% -$3.3M 0.03% 569
2020
Q1 		$28.7M Buy
319,100
+76,300
+31% +$7.49M 0.03% 565
2019
Q4 		$26.3M Buy
242,800
+101,200
+71% +$10.8M 0.02% 811
2019
Q3 		$13.9M Buy
141,600
+67,500
+91% +$7.61M 0.01% 1167
2019
Q2 		$9.71M Buy
74,100
+33,100
+81% +$4.27M 0.01% 1413
2019
Q1 		$5.54M Sell
41,000
-25,200
-38% -$3.13M 0.01% 1697
2018
Q4 		$6.45M Buy
66,200
+16,900
+34% +$2M 0.01% 1609
2018
Q3 		$6.85M Sell
49,300
-19,900
-29% -$2.5M 0.01% 1568
2018
Q2 		$8.59M Sell
69,200
-16,400
-19% -$1.92M 0.01% 1411
2018
Q1 		$9.54M Buy
85,600
+36,700
+75% +$4.39M 0.01% 1274
2017
Q4 		$5.85M Buy
48,900
+12,200
+33% +$1.49M ﹤0.01% 1688
2017
Q3 		$5.15M Sell
36,700
-167,600
-82% -$22.8M ﹤0.01% 1738
2017
Q2 		$24.9M Buy
204,300
+153,400
+301% +$17.9M 0.02% 653
2017
Q1 		$6.17M Buy
50,900
+29,000
+132% +$3.74M 0.01% 1494
2016
Q4 		$2.68M Sell
21,900
-21,500
-50% -$2.63M ﹤0.01% 2590
2016
Q3 		$5.32M Sell
43,400
-5,400
-11% -$695K 0.01% 1613
2016
Q2 		$5.7M Buy
48,800
+19,000
+64% +$2.7M 0.01% 1465
2016
Q1 		$4.15M Sell
29,800
-7,200
-19% -$1.06M ﹤0.01% 1716
2015
Q4 		$7.06M Buy
37,000
+2,100
+6% +$367K 0.01% 1414
2015
Q3 		$5.46M Sell
34,900
-2,600
-7% -$474K 0.01% 1591
2015
Q2 		$6.78M Buy
37,500
+31,600
+536% +$5.45M 0.01% 1488
2015
Q1 		$1.02M Buy
+5,900
New +$1.07M ﹤0.01% 3065
2014
Q1 		– Sell
-73,800
Closed -$9.82M – 7276
2013
Q4 		$9.82M Hold
73,800
– – 0.01% 1264
2013
Q3 		$8.57M Hold
73,800
– – 0.01% 1298
2013
Q2 		$6.81M Buy
+73,800
New +$7.11M 0.01% 1370

Other funds holding ALXN

BCI
Brinker Capital Investments Berwyn, Pennsylvania $11.7B AUM 21.33% 1-Year Est. Return
NICM
Neo Ivy Capital Management New York $379M AUM 28.34% 1-Year Est. Return
TAIM
TD Ameritrade Investment Management Omaha, Nebraska $9.4B AUM 7.2% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return
RG
Retirement Group San Diego, California $279M AUM 22.21% 1-Year Est. Return
CFO
CVA Family Office Denver, Colorado $950M AUM 20.72% 1-Year Est. Return
MAM
Meeder Asset Management Dublin, Ohio $1.75B AUM 34.85% 1-Year Est. Return

Citigroup's ALXN Position: Q3 2021 in Review

Citigroup sold out of Alexion Pharmaceuticals (ALXN) in Q3 2021, closing a stake of 4,404,598 shares — an estimated $809M sold.

Citigroup first reported a position in ALXN in Q2 2013 and held it in 33 quarters. The position peaked at $809M in Q2 2021. 7 funds tracked by Wall St. Rank hold ALXN as of Q3 2021.

  • Citigroup reported no remaining Alexion Pharmaceuticals position as of Q3 2021 after selling out during the quarter.
  • Citigroup sold 4,404,598 Alexion Pharmaceuticals shares in Q3 2021, an estimated $809M.
  • Citigroup first reported a position in Alexion Pharmaceuticals in Q2 2013 and held it in 33 quarters.
  • Citigroup's Alexion Pharmaceuticals position peaked at $809M in Q2 2021.
  • 7 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q3 2021.

Based on Citigroup's 13F filing for Q3 2021, filed 10 Nov 2021.